ChAdOx1 nCoV-19/AZD1222 is an approved adenovirus-based vaccine for severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) currently being deployed globally. Previous …

To combat future severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants
and spillovers of SARS-like betacoronaviruses (sarbecoviruses) threatening global health, …

SARS-CoV-2 emerged in late 2019 and resulted in the ongoing COVID-19 pandemic.
Several animal models have been rapidly developed that recapitulate the asymptomatic to …

Transmission of SARS-CoV-2 is driven by contact, fomite, and airborne transmission. The
relative contribution of different transmission routes remains subject to debate. Here, we show …

Since the emergence of SARS-CoV-2, five different variants of concern (VOCs) have been
identified: Alpha, Beta, Gamma, Delta, and Omicron. Because of confounding factors in the …

Since the start of the COVID-19 pandemic, SARS-CoV-2 has caused millions of deaths
worldwide. Although a number of vaccines have been deployed, the continual evolution of the …

We investigated ChAdOx1 nCoV-19 (AZD1222) vaccine efficacy against SARS-CoV-2
variants of concern (VOCs) B.1.1.7 and B.1.351 in Syrian hamsters. We previously showed …

The major transmission route for SARS-CoV-2 is airborne. However, previous studies could
not elucidate the contribution between large droplets and aerosol transmission of SARS-CoV…

ChAdOx1 nCoV-19 (AZD1222) is a replication-deficient simian adenovirus–vectored
vaccine encoding the spike (S) protein of SARS-CoV-2, based on the first published full-length …

Intramuscular vaccination with ChAdOx1 nCoV-19/AZD1222 protected rhesus macaques
against pneumonia but did not reduce shedding of SARS-CoV-2. Here we investigate whether …